Avita Medical, Inc. · NASDAQ:RCEL
Avita Medical — Q3 2024 Earnings Presentation
19 slides from Avita Medical's earnings presentation, Nov 13, 2024
Slide 1: Investor Presentation November 2024
For personal use only Investor Presentation November 2024
Slide 2: Forward-Looking Statements & Legal Disclaimers
Forward-Looking Statements & Legal Disclaimers This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results, perform
Slide 3: Who We Are
Who We Are Commercial-stage regenerative For personal use only Deliver innovative wound closure medicine company transforming OUR MISSION solutions, enabling transformative patient the standard of care in wound outcomes. care management and skin Become the leading global regenerative restoration wit
Slide 4: Our Leadership
Our Leadership For personal use only J I M CO R B E T T DAV I D O ’ TO O L E N I CO L E K E L S EY D E B B I E GAR N E R RO B I N VAN D E N B U RGH Chief Executive Officer* Chief Financial Officer* Chief Legal and Compliance SVP, Global Marketing & Strategy SVP, U.S. Commercial Sales 30+ Years of Ex
Slide 5: RECELL at the Core of a Comprehensive Portfolio
BUILDING A BROAD-BASED WOUND CARE COMPANY RECELL at the Core of a Comprehensive Portfolio Adjacent Markets of Burn And Full-Thickness Skin Defect Wound Care For personal use only Flagship Device Wound Depth Wound Bed Wound Bed Dermal Dressings Wound Scar Assessment Preparation / Hemostasis Replaceme
Slide 6: Defining the Standard in Wound Care & Skin Regeneration
Defining the Standard in Wound Care & Skin Regeneration For personal use only Wound Bed Epidermal Wound Site Dermal Scaffold Temporizing Replacement Coverage Coming Soon in 2025 Revolutionary biosynthetic Collagen-based dermal First-in-class device Revolutionary transparent matrix for temporizing sc
Slide 7: RECELL Platform
RECELL Platform 2024 2025 For personal use only R EC E L L GO • Two components: multi-use, AC-powered RECELL GO Processing Device (“RPD”) and a RECELL GO UP TO ~10% TOTAL BODY SURFACE UP TO ~2.5% TOTAL BODY Preparation Kit (“RPK”) AREA SURFACE AREA • RPK includes: single-use RECELL GO Cartridge, • L
Slide 8: Accelerating RECELL GO Account Conversions
Accelerating RECELL GO Account Conversions Multiple devices Enhanced Effectively For personal use only maximize operating features reduce treats large wounds room efficiency training burden Burn injury between Burn injury between Burn injury between 10% - 20% TBSA 20% - 30% TBSA 50% - 60% TBSA P8
Slide 9: PermeaDerm: Next Generation Skin Substitute
PermeaDerm: Next Generation Skin Substitute1,2 Dual-Layer Biosynthetic Wound Matrix 1 For personal use only Dressing optimized for protection and moisture management Outer Layer: Slitted 2D Silicone Epidermal Analogue Protects wound from trauma Bacterial barrier Maintains ideal wound moisture for he
Slide 10: Cohealyx: A Collagen Dermal Matrix
Cohealyx: A Collagen Dermal Matrix For personal use only • Unique collagen dermal matrix, which serves as a dermal replacement scaffold • Believed to offer fast integration, revascularization, and consistent skin graft take compared to leading competitive products P 10 Cohealyx is pending FDA cleara
Slide 11: Preliminary Pre-Clinical Wound Bed Preparation & Graft Take
Preliminary Pre-Clinical Wound Bed Preparation & Graft Take¹ Competitor A Competitor B 1 PRE-CLINICAL SKIN GRAFT TAKE For personal use only 120 0 Day Percent Skin Graft Take (Day 7) 100 * 80 Cohealyx² (n=8) 7 Days 60 Competitor A (n=10) 40 Competitor B (n=5) Prior to Skin Grafting 7 Days 20 0 Post-S
Slide 12: Product Compatibility for Full-Thickness Wound
CLINICAL PRESENTATION: FULL-THICKNESS WOUND Product Compatibility for Full-Thickness Wound For personal use only Potential Revenue AVITA Medical Portfolio Per Patient* Dressing optimized for protection and moisture PermeaDerm management $2,000 – $4,000 Robust closure using RECELL + meshed significan
Slide 13: U.S. Market Sizing for Burn and Full-Thickness Skin Defects
RECELL U.S. Market Sizing for Burn and Full-Thickness Skin Defects Total market opportunity of RECELL—eligible procedures For personal use only ~400,000 annual full-thickness skin defects procedures PLUS ~35,000 annual burn procedures Traumatic Wounds Traumatic Wounds Surgical Wounds • Degloving (Op
Slide 14: Summary Future Outlook and Vision
For personal use only Summary Future Outlook and Vision P 14
Slide 15: Global Commercialization Strategy for RECELL
Global Commercialization Strategy for RECELL FOCUSED MARKET For personal use only • Australia • European Union • Japan STRATEGY • Plan to expand exclusively through third-party distribution partners DISTRIBUTION PARTNERS • We have secured agreements in 16 countries: • Australia, Germany, Austria, Sw
Slide 16: Looking Ahead: Q4 2024 Priorities
Looking Ahead: Q4 2024 Priorities > SA L ES E X ECU T I O N • Expand into trauma centers with full-thickness skin defect indication For personal use only • Drive RECELL GO conversions to 95% of our revenue base by year end P RO D U CT P O RT FO L I O E X PAN S I O N > • Expect to receive 510(k) clea
Slide 17: Financial Update
Financial Update Q3 2024 FINANCIAL RESULTS 2024 FINANCIAL GUIDANCE For personal use only Commercial revenue: Commercial revenue: • $19.5 million, an increase of ~44% year-over-year • Q4 2024: expect $22.3 to $24.3 million, representing ~58% to 72% growth year-over-year Gross profit margin: • FY 2024
Slide 18: Quarterly Commercial Revenue
Quarterly Commercial Revenue STRONG COMMERCIAL GROWTH use only $25,000 $23,3001 Revenue (in thousands) $20,000 $19,482 personal $15,133 $15,000 $13,546 $14,097 $11,687 $11,069 $10,458 $10,000 $9,364 40% 42% 50% 29% 44% 65%1 Year-Over-Year Growth Commercial 51% 6% For $5,000 $0 Ryan Zimmerman, BTIG
Slide 19: For personal use only
For personal use only